Healthy Soch
New Delhi, October 25,2019:
1.Dual-acting osteoporosis drug:The recent FDA approval of romosozumab, a new dual-acting drug is giving patients with osteoporosis more control in preventing additional fractures.
2.Expanded use of minimally invasive mitral valve surgery:Expanding the approval of a minimally invasive valve repair device to a population of patients who have failed to get symptom relief from other therapies provides an important new treatment option.
3.Inaugural medication for transthyretin amyloid cardiomyopathy: It is a progressive, underdiagnosed, potentially fatal disease in which amyloid protein fibrils deposit in, and stiffen, the walls of the heart’s left ventricle. But a new agent to prevent misfolding of the deposited protein is showing a significantly reduced risk of death. Following Fast-Track and Breakthrough designations in 2017 and 2018, 2019 marked the FDA approval of tafamidis,the first-ever medication for treatment of this increasingly recognized condition.
4.Therapy for mitigation of peanut allergies: Development of a new oral immunotherapy medicationo gradually build tolerance to peanut exposure holds the opportunity to lend protection against attack.
5.Closed-loop spinal cord stimulation:Implantable devices provide electrical stimulus to the spinal cord but unsatisfactory outcomes due to subtherapeutic or overstimulation events are common. Closed-loop stimulation is allowing for better communication between the device and the spinal cord providing more optimal stimulation and relief of chronic pain.
(To be continued)
healthysoch
